Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Somak Chatterjee
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0000-0002-5011-0094
Observed ORCID:
0000-0002-5011-0094
OpenAlex ID:
A5022111968
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions
2021
·
Janice Kim
, Diana Bradford
, et al.
·
Clinical Cancer Research
·
118
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
2022
·
Timil H. Patel
, Leigh Marcus
, et al.
·
Clinical Cancer Research
·
76
PDF
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2023
·
Katie Chon
, Erin Larkins
, et al.
·
Clinical Cancer Research
·
69
PDF
FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer
2022
·
Elizabeth S. Duke
, Amy K. Barone
, et al.
·
Clinical Cancer Research
·
60
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis
2024
·
Bernardo Haddock Lobo Goulart
, Sirisha L Mushti
, et al.
·
The Lancet Oncology
·
55
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
2025
·
Sonia Singh
, Diana Bradford
, et al.
·
Clinical Cancer Research
·
36
Evaluation of the correlation between antibiotic use and survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs).
2020
·
Paz J. Vellanki
, Shanthi Marur
, et al.
·
Journal of Clinical Oncology
·
10
Association of progression-free survival and overall response rate with overall survival in first-line randomized trials of immune checkpoint inhibitor–based regimens for metastatic non–small cell lung cancer (NSCLC): An FDA pooled analysis.
2022
·
Bernardo Haddock Lobo Goulart
, Sirisha Mushti
, et al.
·
Journal of Clinical Oncology
·
4
Supplementary Table S1 from FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
2025
·
Sonia Singh
, Diana Bradford
, et al.
·
1
A pooled analysis of response to selective RET inhibitors among patients with medullary thyroid cancer with M918T versus non-M918T RET mutations.
2021
·
Janice Kim
, Diana Bradford
, et al.
·
Journal of Clinical Oncology
·
1
FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
2026
·
Rachel Ershler
, Xueping Zhou
, et al.
·
Clinical Cancer Research
PDF
Supplementary Table S1: Exploratory analysis of ORR by clinical and demographic subgroups from FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2025
·
Katie Chon
, Erin Larkins
, et al.
PDF
Data from FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2025
·
Katie Chon
, Erin Larkins
, et al.
Data from FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
2025
·
Sonia Singh
, Diana Bradford
, et al.
Show more works
View as search
Works count:
14
Citation count:
430
H-index:
7
I10-index:
7
Year
Topic
Type